CN111888326B - 羟甲唑啉组合物和用于治疗眼障碍的方法 - Google Patents

羟甲唑啉组合物和用于治疗眼障碍的方法 Download PDF

Info

Publication number
CN111888326B
CN111888326B CN202010249167.7A CN202010249167A CN111888326B CN 111888326 B CN111888326 B CN 111888326B CN 202010249167 A CN202010249167 A CN 202010249167A CN 111888326 B CN111888326 B CN 111888326B
Authority
CN
China
Prior art keywords
formulation
weight
certain aspects
chloride
points
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010249167.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN111888326A (zh
Inventor
T·德弗里斯
D·雅各布斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RVL Pharmaceuticals Inc
Original Assignee
RVL Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RVL Pharmaceuticals Inc filed Critical RVL Pharmaceuticals Inc
Priority to CN202310901249.9A priority Critical patent/CN117045596A/zh
Publication of CN111888326A publication Critical patent/CN111888326A/zh
Application granted granted Critical
Publication of CN111888326B publication Critical patent/CN111888326B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202010249167.7A 2019-05-06 2020-04-01 羟甲唑啉组合物和用于治疗眼障碍的方法 Active CN111888326B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310901249.9A CN117045596A (zh) 2019-05-06 2020-04-01 羟甲唑啉组合物和用于治疗眼障碍的方法

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962844069P 2019-05-06 2019-05-06
US201962843819P 2019-05-06 2019-05-06
US62/844,069 2019-05-06
US62/843,819 2019-05-06
US16/716,014 2019-12-16
US16/716,014 US10799481B1 (en) 2019-05-06 2019-12-16 Compositions and methods for treating ocular disorders
US16/715,998 US10814001B1 (en) 2019-05-06 2019-12-16 Oxymetazoline compositions
US16/715,998 2019-12-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310901249.9A Division CN117045596A (zh) 2019-05-06 2020-04-01 羟甲唑啉组合物和用于治疗眼障碍的方法

Publications (2)

Publication Number Publication Date
CN111888326A CN111888326A (zh) 2020-11-06
CN111888326B true CN111888326B (zh) 2023-07-21

Family

ID=72750169

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010249167.7A Active CN111888326B (zh) 2019-05-06 2020-04-01 羟甲唑啉组合物和用于治疗眼障碍的方法
CN202310901249.9A Pending CN117045596A (zh) 2019-05-06 2020-04-01 羟甲唑啉组合物和用于治疗眼障碍的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310901249.9A Pending CN117045596A (zh) 2019-05-06 2020-04-01 羟甲唑啉组合物和用于治疗眼障碍的方法

Country Status (16)

Country Link
US (11) US10814001B1 (https=)
EP (1) EP3965737A1 (https=)
JP (3) JP7141420B2 (https=)
KR (3) KR102410503B1 (https=)
CN (2) CN111888326B (https=)
AU (1) AU2020268329B2 (https=)
BR (1) BR112021022404A2 (https=)
CL (1) CL2021002918A1 (https=)
CO (1) CO2021015265A2 (https=)
IL (1) IL287831A (https=)
MA (1) MA55895A (https=)
MX (1) MX2021013516A (https=)
PE (1) PE20220384A1 (https=)
SG (1) SG11202112272TA (https=)
WO (1) WO2020227260A1 (https=)
ZA (2) ZA202108950B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
WO2022187306A1 (en) 2021-03-03 2022-09-09 Voom, Llc Compositions and methods for treatment of blepharitis
WO2023079427A1 (en) * 2021-11-03 2023-05-11 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006131628A (ja) * 2004-10-08 2006-05-25 Rohto Pharmaceut Co Ltd オキシメタゾリン含有水性組成物
CN1832726A (zh) * 2003-08-13 2006-09-13 默克专利有限公司 包含羟甲唑啉和/或赛洛唑啉的水性药物溶液
CN101951886A (zh) * 2007-12-21 2011-01-19 先灵-普劳健康护理产品公司 增强羟甲唑啉的光稳定性
CN103501771A (zh) * 2011-03-03 2014-01-08 沃姆有限责任公司 用于上睑下垂的非手术治疗的组合物和方法
CN104023707A (zh) * 2011-04-26 2014-09-03 睿德制药有限公司 用于治疗肛门直肠疾患的羟甲唑啉

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5888493A (en) 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
JP2002249445A (ja) 2000-12-19 2002-09-06 Ophtecs Corp 眼科用液剤組成物
US6806364B2 (en) 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
CN101327325A (zh) * 2002-07-30 2008-12-24 奥默罗斯公司 眼科冲洗液及方法
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
AU2007227091B2 (en) 2006-03-17 2013-02-07 Johnson & Johnson Vision Care, Inc. Stabilized ophthalmic compositions comprising oxidatively unstable components
CA2650592A1 (en) 2006-04-26 2007-11-08 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
WO2008070185A2 (en) * 2006-12-06 2008-06-12 The Trustees Of Columbia University In The City Of New York Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
WO2009061431A2 (en) 2007-11-08 2009-05-14 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
JP5581227B2 (ja) * 2008-03-11 2014-08-27 アルコン リサーチ， リミテッド 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤
WO2010141831A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
US20120082625A1 (en) 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
AU2011327785A1 (en) * 2010-11-08 2013-03-07 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
US8883838B2 (en) 2010-12-03 2014-11-11 Allergan, Inc. Pharmaceutical cream compositions and methods of use
JP2015518006A (ja) 2012-05-25 2015-06-25 エクスクリア インコーポレイテッド キシリトール系の抗粘膜組成物及び関連する方法並びに組成物
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
CN106034406B (zh) 2013-09-18 2019-09-10 迈康尼股份公司 对smt系统操作员提供信息的方法、系统和设备
AU2015274532B2 (en) 2014-06-11 2020-06-11 Epi Health, Llc Stabilized oxymetazoline formulations and their uses
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
US20170312335A1 (en) * 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation
CN108883308A (zh) 2016-01-26 2018-11-23 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
CN105997856A (zh) * 2016-06-24 2016-10-12 魏威 盐酸羟甲唑啉滴眼液及其制备方法
US11246816B2 (en) 2016-06-30 2022-02-15 The Procter And Gamble Company Shampoo compositions comprising a chelant
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1832726A (zh) * 2003-08-13 2006-09-13 默克专利有限公司 包含羟甲唑啉和/或赛洛唑啉的水性药物溶液
JP2006131628A (ja) * 2004-10-08 2006-05-25 Rohto Pharmaceut Co Ltd オキシメタゾリン含有水性組成物
CN101951886A (zh) * 2007-12-21 2011-01-19 先灵-普劳健康护理产品公司 增强羟甲唑啉的光稳定性
CN103501771A (zh) * 2011-03-03 2014-01-08 沃姆有限责任公司 用于上睑下垂的非手术治疗的组合物和方法
CN104023707A (zh) * 2011-04-26 2014-09-03 睿德制药有限公司 用于治疗肛门直肠疾患的羟甲唑啉

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The effects of nasal decongestion on obstructive sleep apnoea;Yunsong An等;《Am J Otolaryngol》;第40卷;52-56 *

Also Published As

Publication number Publication date
US20230355587A1 (en) 2023-11-09
CL2021002918A1 (es) 2022-08-19
US20210386711A1 (en) 2021-12-16
US10898573B1 (en) 2021-01-26
KR20200128629A (ko) 2020-11-16
US11701343B2 (en) 2023-07-18
KR102663319B1 (ko) 2024-05-03
US20240033250A1 (en) 2024-02-01
US11103482B2 (en) 2021-08-31
US11541036B2 (en) 2023-01-03
US11324722B2 (en) 2022-05-10
US20210212992A1 (en) 2021-07-15
EP3965737A1 (en) 2022-03-16
SG11202112272TA (en) 2021-12-30
ZA202108950B (en) 2023-10-25
CN117045596A (zh) 2023-11-14
AU2020268329B2 (en) 2026-01-15
JP7141420B2 (ja) 2022-09-22
KR102859351B1 (ko) 2025-09-12
IL287831A (en) 2022-01-01
US20220273621A1 (en) 2022-09-01
CA3139443A1 (en) 2020-11-12
US20210137889A1 (en) 2021-05-13
KR102410503B1 (ko) 2022-06-17
NZ782902A (en) 2024-09-27
WO2020227260A1 (en) 2020-11-12
US20220257566A1 (en) 2022-08-18
US11311515B2 (en) 2022-04-26
JP2021191802A (ja) 2021-12-16
MX2021013516A (es) 2022-01-24
JP7705326B2 (ja) 2025-07-09
KR20240060580A (ko) 2024-05-08
BR112021022404A2 (pt) 2022-01-18
AU2020268329A1 (en) 2022-01-06
PE20220384A1 (es) 2022-03-18
US20200353083A1 (en) 2020-11-12
ZA202212328B (en) 2025-03-26
US12605363B2 (en) 2026-04-21
US20210015795A1 (en) 2021-01-21
KR20220084264A (ko) 2022-06-21
US10940138B2 (en) 2021-03-09
US10799481B1 (en) 2020-10-13
CO2021015265A2 (es) 2022-02-28
JP2020183373A (ja) 2020-11-12
US20210023222A1 (en) 2021-01-28
JP2025065198A (ja) 2025-04-17
US10814001B1 (en) 2020-10-27
CN111888326A (zh) 2020-11-06
MA55895A (fr) 2022-03-16

Similar Documents

Publication Publication Date Title
KR102859351B1 (ko) 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법
AU2022409839B2 (en) Ophthalmic pharmaceutical compositions and uses thereof
RU2820596C2 (ru) Композиции оксиметазолина и способы для лечения офтальмологических расстройств
CA3139443C (en) Oxymetazoline compositions and methods for treating ocular disorders
HK40100508A (zh) 羟甲唑啉组合物和用於治疗眼障碍的方法
HK40031931B (zh) 羟甲唑啉组合物和用於治疗眼障碍的方法
HK40031931A (en) Oxymetazoline compositions and methods for treating ocular disorders
CN103202833A (zh) 一种奥洛他定或其盐的药用组合物及其制备方法
BR122024023871A2 (pt) Formulações livres de conservantes oftálmicas aquosas farmaceuticamente estáveis, recipientes de uso único, bem como usos terapêuticos das ditas formulações

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40031931

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant